Pfizer is about to swap out one of its top number crunchers. The drug giant said Thursday that Chief Financial Officer Dave Denton will step down and leave the company on August 15 to take a job in the consumer goods world, putting an end to a little over two years in Pfizer’s top finance seat.
Cecile Guegan, senior vice president of finance for Pfizer’s global biopharmaceutical business, will step in as interim CFO on August 16 while the company runs a global search for a permanent successor. Company leaders said Denton and Guegan will work side by side over the summer to keep the handoff from getting bumpy.
In a press release via Pfizer, the company said Denton "will step down from his current role and leave the company on August 15" and confirmed that he has accepted "a professional opportunity outside of the pharmaceutical industry in consumer goods." The statement said Pfizer has launched a "comprehensive internal and external search" for his replacement and named Guegan interim CFO effective August 16. CEO Albert Bourla used the announcement to thank Denton for helping steer Pfizer through a run of major strategic transactions.
Denton joined Pfizer as CFO in May 2022 after serving in senior finance roles at Lowe’s and CVS, according to an earlier announcement by Business Wire. Pfizer’s latest announcement credits him with helping shepherd the big-ticket deals that reshaped the company’s pipeline, including the roughly $43 billion acquisition of Seagen that was announced in 2023, per an SEC filing. Those transactions have driven heavy financing and integration work across Pfizer’s finance organization.
Guegan Steps In As Interim CFO
Pfizer tapped Cecile Guegan as interim CFO, pointing to her more than twenty years inside the company and her current role overseeing finance across the global biopharmaceutical business, including the integration of Seagen, according to Pfizer. In that release, Bourla said he had "every confidence" in Guegan’s ability to lead the finance organization while the search for a permanent successor plays out.
What Investors Will Be Watching
On Wall Street, eyes will be on how Pfizer’s finance team manages the ongoing integration work and the company’s debt load after its deal spree. Regulatory filings show that Pfizer financed a portion of the Seagen purchase with about $31 billion of long term notes issued in May 2023, a level of indebtedness that will heavily influence the next CFO’s agenda and capital allocation plans. See Pfizer for more detail on financing and debt levels in the company’s 2023 Form 10 K.
With Denton set to walk out on August 15, Pfizer has a little over two months to steady the finance leadership lineup and advance its search for a permanent replacement. Executives and investors alike will be looking for a CFO with serious deal-making chops and capital markets credibility to handle integration work, manage the balance sheet and keep the long term strategy on track.
